| 1.68 -0.09 (-5.08%) | 10-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.26  |
1-year : | 2.51 |
| Resists | First : | 1.93 |
Second : | 2.14 |
| Pivot price | 1.84 |
|||
| Supports | First : | 1.6 |
Second : | 1.33 |
| MAs | MA(5) : | 1.78 |
MA(20) : | 1.87 |
| MA(100) : | 1.95 |
MA(250) : | 2.5 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 16.8  |
D(3) : | 18.2 |
| RSI | RSI(14): 31.5 |
|||
| 52-week | High : | 4.94 | Low : | 1.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BDTX ] has closed below the lower bollinger band by 16.9%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ BDTX ] is to continue within current trading range. It is unclear right now based on current values. 58.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.77 - 1.78 | 1.78 - 1.79 |
| Low: | 1.58 - 1.59 | 1.59 - 1.6 |
| Close: | 1.66 - 1.68 | 1.68 - 1.7 |
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Fri, 02 Oct 2026
Black Diamond Therapeutics Inc (BDTX-Q) Stock Price and News - The Globe and Mail
Fri, 02 Oct 2026
BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview - ChartMill
Mon, 21 Sep 2026
Black Diamond (NASDAQ: BDTX) director takes stock in lieu of cash fees - Stock Titan
Wed, 02 Sep 2026
Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Wed, 05 Aug 2026
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire
Mon, 06 Jul 2026
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 57 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 72.5 (%) |
| Shares Short | 4,780 (K) |
| Shares Short P.Month | 6,120 (K) |
| EPS | -0.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.66 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.2 % |
| Return on Equity (ttm) | -37.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.78 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -2.25 |
| PEG Ratio | 0 |
| Price to Book value | 1 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|